Yetzugo is a long-acting HIV-1 capsid inhibitor that reduces the risk of sexually acquired HIV in adults and adolescents.

What kind of uptake can Gilead Sciences expect for its highly touted, long-acting HIV pre-exposure prophylaxis (PrEP) ...

Gilead Sciences (NasdaqGS:GILD) recently entered an exclusive agreement with Kymera Therapeutics to advance a molecular glue degrader program targeting CDK2, enhancing its oncology pipeline.

The US Food and Drug Administration (FDA) has approved lenacapavir as a long-acting injectable drug to prevent HIV.

Kymera’s programme focuses on removing CDK2 from cells compared to other therapies that target the protein’s inhibition.

Teen idol Bobby Sherman dies at 81 Sherman had four Top 10 hits on the Billboard Hot 100 chart: “Little Woman,” “Julie, Do Ya Love Me,” “Easy Come, Easy Go,” and “La La La (If I Had You).” ...